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renal disease.
Background. Mast cells are growth factor–rich, bone mar-
row–derived cells that infiltrate injured tissue where they have
been implicated in the pathogenesis of progressive fibrosis.
Methods. Mast cell infiltration and the expression of related
chemoattractants was examined following 5/6 nephrectomy, a
model of progressive, nonimmune-mediated renal injury. In
addition, expression of the profibrotic cytokine, transforming
growth factor- (TGF-) within mast cells and the effects of
renoprotective therapy with angiotensin-converting enzyme
(ACE) inhibition were also determined.
Results. Renal injury was accompanied by mast cell infiltra-
tion, in close proximity to areas of tubulointerstitial fibrosis.
Mast cells displayed toluidine blue metachromasia and were
immunopositive for TGF-1 as well as chymase and tryptase.
The expression of several mast cell chemokines, including stem
cell factor, interleukin-8 (IL-8), and also TGF-1, were in-
creased in 5/6 nephrectomized kidneys. ACE inhibition with
ramipril led to a reduction in renal injury in association with
attenuation of mast cell infiltration and chemokine expression.
Conclusion. Mast cell infiltration and related chemokine ex-
pression are prominent and early features following renal mass
reduction and may contribute pathogenetically to progressive
renal injury.
Activation and phenotypic changes to resident renal
cells, such as myofibroblasts, contribute to the pathogen-
esis of progressive kidney disease [1]. Studies conducted
over the past decade have also indicated a role for infil-
trating inflammatory cells, principally macrophages in
renal disease progression [2, 3]. However, other cellular
components of the immune system, including mast cells,
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have additionally been implicated in the pathogenesis of
nonimmune renal disease [4].
While mast cells are traditionally known for their role
in allergic immunoglobulin E (IgE)-mediated reactions,
there is also a nonimmune-related mast cell phenotype
that predominates in connective tissue, rather than at
mucosal surfaces [5]. These nonimmune mast cells partic-
ipate in cell migration, differentiation, and, in particular,
the synthesis of extracellular matrix and the formation
of fibrotic scar tissue [5]. Indeed, mast cell infiltration
has not only been documented in a wide range of human
renal diseases [6–11], but a close relationship with the
extent of interstitial fibrosis and impaired renal function
has also been reported [8].
Mast cells, derived from hematopoietic progenitors,
leave the bone marrow and migrate to areas of inflam-
mation. A number of factors responsible for this direc-
tional migration and tissue maturation of mast cells have
been identified [12]. These include the CXC family of
chemokines [13], stem cell factor (also known as kit-
ligand, steel factor, and mast cell growth factor) [14, 15],
and transforming growth factor- (TGF-) [16].
The present study first sought to examine the develop-
ment of mast cell infiltration and the expression of related
chemoattractants following subtotal nephrectomy, a model
of progressive, nonimmune mediated renal injury. This
study also sought to determine whether the profibrotic
cytokine, TGF-, found in mast cells at other sites, was
also present in kidney mast cells. In addition, the study
also sought to determine the effects of renoprotective
therapy with angiotensin-converting enzyme (ACE) in-
hibition on mast cell numbers and chemokine expression.
METHODS
To determine the time course of mast cell infiltration
and chemoattractant expression, 40 male Sprague-Daw-
ley rats weighing 200 to 250 g were randomized to five
groups of 10 animals each. Ten animals were assigned to
undergo sham surgery and the remaining 30 underwent
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subtotal nephrectomy. Among the latter, rats were as-
signed for sacrifice at 4 weeks and 12 weeks after surgery.
Animals studied for 12 weeks were further assigned to
treatment with or without the ACE inhibitor, ramipril
(3 mg/L drinking water). Anesthesia was achieved by
the intraperitoneal administration of pentobarbital (6
mg/100 g body weight) (Boehringer Ingelheim, Artar-
mon, NSW, Australia). The control group underwent
sham surgery consisting of laparotomy and manipulation
of both kidneys before wound closure. The other 30 rats
all underwent subtotal nephrectomy performed by right
subcapsular nephrectomy and infarction of approxi-
mately two thirds of the left kidney by selective ligation
of two of three to four extrarenal branches of the left
renal artery [17]. Rats were housed in a temperature
(22C)-controlled room with ad libitum access to com-
mercial standard rat chow (Norco Co-Operative Ltd.,
Lismore, NSW, Australia) and water during the entire
study. At sacrifice, the remnant (left) kidney was then
sliced sagitally and one half immersion-fixed in 10% neu-
tral buffered formalin and embedded in paraffin for his-
tochemical and immunohistochemical studies. The re-
maining half was snap-frozen in liquid nitrogen and
stored at –80C for subsequent gene expression analyses.
All experiments adhered to the guidelines of the Animal
Welfare and Ethics Committee of St. Vincent’s Hospital
and the National Health and Medical Research Founda-
tion of Australia.
Renal function
Body weight was measured weekly. Plasma urea and
creatinine were measured by autoanalyzer (Beckman
Instrumentals, Palo Alto, CA, USA) at the beginning
and end of the study. Glomerular filtration rate (GFR)
was measured prior to sacrifice by a single shot of 99m-
technetium diethylenetriamine pentaacetic acid (Tc99m-
DTPA) clearance [18]. Systolic blood pressure was
measured in conscious rats using an occlusive tail-cuff
plethysmograph attached to a pneumatic pulse trans-
ducer (Narco Bio-system, Inc., Houston, TX, USA) [19].
Before sacrifice, rats were housed in metabolic cages for
24 hours for subsequent measurement of urinary protein
excretion using the Coomassie brilliant blue method.
Histochemistry and immunohistochemistry
Four micron sections were cut and examined after
either histochemical or immunohistochemical staining.
Histochemical staining comprised the use of either hema-
toxlyin and eosin, Masson’s trichrome, and periodic-acid
Schiff (PAS) stains to examine extracellular matrix. Mast
cells were identified in serial sections stained with tolu-
idine blue, chymase, tryptase, and TGF-. Macrophages
were identified by immunostaining with a monoclonal
antibody specific for the monocyte/macrophage antigen,
ED-1 (Serotec, London, UK). Toluidine blue staining
was performed by immersion of sections in 0.1% tolu-
idine blue (Sigma Chemical Co., St. Louis, MO, USA)
for 1 minute at room temperature with mast cells, identi-
fied by their characteristic metachromasia [20]. Mast cells
and macrophages were quantified in 25 randomly se-
lected, nonoverlapping fields and expressed as the num-
ber of mast cells/mm2. Immunostaining for chymase,
tryptase, and TGF-1 was also performed using a mono-
clonal antichymase (Chemicon, Temecula, CA, USA),
monoclonal antitryptase (Chemicon) and polyclonal rab-
bit antihuman TGF-1 (Santa Cruz Biotechnology, Santa
Cruz, CA, USA) antibodies. Stem cell factor (SCF-1)
was localized using a polyclonal rabbit antirat antibody
(Santa Cruz Biotechnology). Immunohistochemistry was
performed, as previously described [21] with visualiza-
tion using the indirect avidin-biotin complex (ABC)
method.
Renal structure
Changes in kidney structure were assessed in a masked
protocol in at least 25 randomly selected tissue sections
from each group studied. Sections were stained with
either Mayer’s hematoxylin and eosin to examine cell
structure, PAS, or Masson’s modified trichrome to dem-
onstrate collagen matrix [22].
Glomerulosclerosis. In 4 m kidney sections stained
with PAS, 50 to 80 glomeruli from rats were examined.
The degree of sclerosis in each glomerulus was subjec-
tively graded on a scale of 0 to 4 as previously described
[23]: grade 0, normal; grade 1, sclerotic area up to 25%
(minimal); grade 2, sclerotic area 25% to 50% (moder-
ate); grade 3, sclerotic area 50% to 75% (moderate to
severe); and grade 4, sclerotic area 75% to 100% (se-
vere). A glomerulosclerotic index (GSI) was then calcu-
lated using the formula:
4
GSI   Fi (i)
i  0
where Fi is the % of glomeruli in the rat with a given
score (i) [18].
Tubulointerstitial fibrosis. The accumulation of matrix
within the tubulointerstitium was estimated on Masson’s
trichrome–stained sections using computer-assisted im-
age analysis, as previously reported [24, 25]. Briefly, five
random nonoverlapping fields from each rat were cap-
tured and digitized using a BX50 microscope attached
to a Fujix HC5000 digital camera (Fuji, Tokyo, Japan).
Digital images were then loaded onto a Pentium III IBM
computer (Gateway, Los Angeles, CA). An area of blue
on a trichrome-stained section was selected for its color
range and the proportional area of tissue with this range
of color was then quantified. Calculation of the propor-
tional area stained blue (matrix) was then determined
using image analysis (AIS, Analytical Imaging Station
Version 6.0, Toronto, Ontario, Canada).
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Table 1. Primers and probes for rat interleukin-8 (IL-8)/gro-, stem
cell factor (SCF) and transforming growth factor- (TGF-1)
IL-8/gro-
Forward primer AGAACATCCAGAGTTTGAAGGTGAT
Reverse primer GTGGCTATGACTTCGGTTTGG
Probe CCGCCAGGACCCCACTGCA
SCF
Forward primer CAGTAATAGGAAAGCCGCAAAGTC
Reverse primer GCCGGCAGTGCCATTG
Probe CTGAAGACCCGGGCCTACAATGGAC
TGF-ß1
Forward primer AGAAGTCACCCGCGTGCTA
Reverse primer TGTGTGATGTCTTTGGTTTTGTCA
Probe TGGTGGACCGCAACAACGCAAT
RNA extraction and cDNA synthesis
Frozen kidney tissue, stored at 80C, was homoge-
nized (Polytron, Kinematica Gmbh, Littau, Switzerland)
and total RNA was isolated using TRIzol reagent (Life
Technologies, Grand Island, NY, USA). The purified
RNA was dissolved in sterile water and quantified spec-
trophotometrically (OD260). RNA quality was verified
on a 1% denaturing agarose gel. Four micrograms of
total RNA was treated with RQ1 DNase (1 U/L) (Pro-
mega, Madison, WI, USA) to remove genomic DNA.
The DNase treated RNA was reverse transcribed with
1 L (2 g/L) random hexamers (Roche Diagnostics,
Mannheim, Germany) and incubated for 5 minutes at
70C. After cooling on ice for 5 minutes, 5 L of 5 
avian myelomatosis virus (AMV) reaction buffer, 2.5 L
of 10 mmol/L desoxynucleoside triphosphate (dNTP)
mix, 0.5 L RNase inhibitor (40 U/L) (Roche Diagnos-
tics, Mannheim, Germany), 0.5 L AMV reverse tran-
criptase (25 U/L) (Roche Diagnostics) and 4.5 L of
diethyl pyrocarbonate (DEPC) water was added. Tubes
were incubated at 37C for 60 minutes, after which cDNA
samples were stored at 20C for future use.
Quantitative real-time polymerase chain reaction
Using rat specific sequence primers (Table 1), the gene
expression of three mast cell chemokines, interleukin-8
(IL-8)/gro-, SCF-1, and TGF-1, were quantified by
real-time reverse transcription-polymerase chain reac-
tion (RT-PCR), as previously described [26]. A commer-
cial, predeveloped 18S control kit with [TAMRA] on
the 3 end (PE Biosystems, Foster City, CA, USA) was
used as the housekeeping gene to control for inequalities
of loading. Primers and probes for target genes were
obtained from PE Biosystems. Both probes included a
fluorescence reporter (6-carboxyfluorescein [FAM]) at
the 5-end and a fluorescent quencher (6-carboxytetra-
methylrhodamine [TAMRA]) at the 3-end. For the rela-
tive quantification of the target gene and the endogenous
reference 18S ribosomal RNA (18S), real-time quantita-
tive RT-PCR was performed using an GeneAmp 5700
Sequence Detector (PE Biosystems) according to the
manufacturer’s instructions. The derived normalized val-
ues were the averages of four runs. Results were ex-
pressed as the ratio of IL-8/gro-, TGF-1, or SCF mRNA
to 18S relative to sham kidney, which were arbitrarily
assigned a value of 1.
Statistics
All data are shown as mean 	 SEM unless otherwise
specified. Data were analyzed by analysis of variance
(ANOVA) using the StatView IV program (Brainpower,
Calabasas, CA, USA) on a Macintosh G4. Comparisons
between group means were performed by Fisher’s least
significant difference method. A P value of less than 0.05
was considered statistically significant.
RESULTS
Clinical parameters
Subtotal nephrectomy led to the development of pro-
gressive renal scarring with associated hypertension, pro-
teinuria and impaired glomerular filtration rate (GFR).
All of these changes were attenuated with ramipril treat-
ment (Table 2).
Mast cells and macrophages
Only an occasional mast cell was identified in the kid-
neys of sham-operated rats. In contrast, significant infil-
tration of toluidine blue–positive mast cells were noted
in the tubulointerstitium of rats that had undergone sub-
total nephrectomy (Fig. 1). In particular, mast cells were
noted in areas of tubular dilatation and interstitial fibro-
sis, but not noted within the glomerular tuft. The extent
of mast cell infiltration was greater at 12 weeks than at
4 weeks and was significantly reduced in kidneys from
ramipril-treated rats. In serial sections, toluidine blue–
stained mast cells also showed positive immunostaining
for chymase, tryptase, and TGF-1 (Fig. 2). Mast cells
were mostly found in areas that also included abundant
ED-1–labeled macrophages (Fig. 3). At 12 weeks, the
ratio of macrophages to mast cells was 15:1 (macro-
phages 404 	 11/mm2, mast cells 26 	 6/mm2; P 
 0.01).
Mast cell chemokines
Expression of IL-8/gro-was increased at 4 weeks and
to a greater extent at 12 weeks after subtotal nephrec-
tomy (Fig. 4). TGF-mRNA followed a similar chronol-
ogy. In contrast, SCF was not elevated at 4 weeks but
only at 12 weeks after renal mass reduction. The over-
expression of all three mast cell chemokines, IL-8/gro-,
TGF-, and SCF, was attenuated by ramipril (Fig. 4).
SCF expression was mostly undetectable in sham-oper-
ated rats but was present in tubules of rats that had
undergone 5/6 nephrectomy (Fig. 5).
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Table 2. Clinical parameters at end of study
12 weeks  angiotensin-converting
Sham 4 weeks 12 weeks enzyme inhibitor
Number 10 10 10 10
Body weight g 491	13 324	9 436	19 401	23
Systolic blood pressure mm Hg 115	3 176	8a 180	15a 121	8b
Glomerular filtration rate mL/min/L 4.0	0.2 0.6	0.3a 0.7	0.2a 1.7	0.1a,b
Urinary protein g/day 13	2 26	16a 211	86a 23	6b
Glomerulosclerotic index 0.3	0.0 2.0	0.3a 3.1	0.4a 1.5	0.4a
Tubulointerstitial fibrosis % area 0.0	0.1 2.0	0.6a 3.6	1.0a 1.4	0.4a,b
Data expressed as mean 	 SEM.
aP 
 0.01 vs. sham; bP 
 0.01 vs. 12 weeks
Fig. 1. Mast cells in subtotal nephrectomy. ACEI is angiotensin-con-
verting enzyme inhibitor.
DISCUSSION
The pathogenesis of progressive renal injury following
an initial insult remains incompletely understood. While
the role of macrophages and their chemotactic factors
in kidney disease has been widely examined [2, 27], other
bone marrow–derived cells have not been extensively
studied. The present study identifies a number of novel
findings in relation to the pathogenesis of renal injury
that follows renal mass reduction, a nonimmune model
of progressive of renal disease [28]. First, mast cell infil-
tration was a prominent and early feature following renal
injury. Second, mast cells in the injured kidney were
found to contain TGF-1, as well as chymase and tryp-
tase. Third, we found that a range of mast cell chemo-
kines were elevated in the setting of renal injury, with
early induction of TGF- and IL-8/gro-, while SCF was
expressed later in the course of disease. Finally, ACE
inhibitor treatment was associated with attenuation in
chemokine expression and mast cell infiltration.
In addition to their well-established role in allergic
disease, mast cells have also been repeatedly implicated
in the pathogenesis of fibrotic scarring [29]. For instance,
mast cells are particularly abundant at the site of active
lesions in scleroderma [30], a chronic disorder character-
ised by progressive skin and extradermal fibrosis affect-
ing multiple tissue sites, including the kidney. Mast cell
infiltration has also been documented in a range of kid-
ney diseases where their presence in the tubulointerstit-
ium correlates closely with collagen–synthesizing myo-
fibroblasts [31]. In particular, mast cells have been noted
to be most abundant in diabetic nephropathy [11], IgA
nephropathy [7], and in rapidly progressive glomerulo-
nephritis, where mast cells numbers correlates closely
with both tubulointerstitial pathology and declining
GFR [8].
Mast cells secrete a range of factors that may contrib-
ute to renal injury, including endothelin [21], growth
factors, and the proteolytic enzymes implicated in the
pathogenesis of renal disease. For instance, the major
mast cell enzyme, tryptase, promotes renal fibroblast
proliferation and collagen synthesis, particularly in com-
bination with heparin, another mast cell secretory prod-
uct [10]. Chymase, in addition to its potential role in
angiotensin II generation, also converts the latent, bio-
logically inactive form of TGF- into an active form
recognized by its type II receptor [32]. TGF- is a potent
profibrotic growth factor that is widely implicated in the
pathogenesis of progressive renal disease [33]. While
TGF- containing mast cells have been previously re-
ported [32, 34], the present study is the first to identify
them within the kidney. Indeed, the presence of both
TGF- and chymase within mast cell granules, as demon-
strated in this study, suggests that mast cell degranulation
will be followed by the liberation and subsequent activa-
tion of TGF-.
Identification of TGF- containing mast cell infiltra-
tion suggests a role in renal fibrosis. Other TGF- con-
taining bone marrow–derived cells, such as macrophages,
were also identified in the present study as even more
abundant. However, the enormous secretory, storage,
and synthetic capacity of the mast cell [35] suggests that
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Fig. 2. Photomicrographs of mast cells within
the kidney of subtotally nephrectomized rats.
Chymase-positive mast cells (A ) (arrows) lo-
calized to the cortical interstitium (magnifica-
tion280). Serial sections showing an intersti-
tial mast cell in close proximity to a vessel (*)
demonstrating toluidine blue metachromasia
(B), and positive immunostaining for tryptase
(C) and transforming growth factor- (TGF-)
(D) (magnification 1020).
Fig. 3. Serial sections showing (A) toluidine
blue–stained mast cells (arrows) and (B) ED-1
immunopositive macrophages (arrows) local-
ized to the interstitium and adjacent to a tu-
bule (*) (magnification 520).
it may contribute disproportionately to the quantity of
TGF- in the local milieu.
The profibrotic contents of the mast cell suggest that
it has an active, pathogenetic role in renal fibrosis, rather
than that of a bystander [12]. In the present study, mast
cells were closely associated with areas of tubulointersti-
tial fibrosis and tubular atrophy. While not specifically
tested in the kidney, the active role of the mast cell in
the process of organ injury has recently been definitively
shown in a mouse model of heart failure [36]. Using the
W/Wv mouse, Hara et al [36] demonstrated a significant
reduction in both cardiac fibrosis and ventricular dys-
function when these mast cell–deficient animals were
subjected to aortic banding.
Several factors have been identified as mast cell che-
moattractants. These include chemokines such as IL-8,
growth factors like TGF-, and the ligand for the mast
cell c-kit receptor, SCF [14–16]. Chemokines are a family
of cytokines responsible for the chemotaxis of inflamma-
tory cells. It consists of four subfamilies that are classified
on the basis of their constituent cysteine residues as C,
CC, CXC, and C(X3)C chemokines [37]. Recent studies
have indicated that of this array, only a subtype of the
CXC chemokines, those with a conserved glutamate-
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Fig. 4. Mast cell chemokines. Graphs showing gene expression of (A)
stem cell factor (SCF), (B) interleukin-8 (IL-8/gro-) and (C) trans-
forming growth factor-1 (TGF-1) relative to the housekeeping gene
18S, as assessed by real-time polymerase chain reaction (PCR). Results
are expressed in arbitrary units relative to sham, assigned a value of 1.
*P 
 0.01 vs. sham; †P 
 0.01 vs. 12 weeks.
leucine-arginine (ELR) motif are chemotactic for mast
cells [13]. In the present study, IL-8/gro- was dramati-
cally up-regulated early in the course of renal disease and
also increased in the later disease stages, commensurate
with both progressive injury and mast cell infiltration.
In the present study, early up-regulation of TGF-
was also noted. While TGF- in the kidney is mostly
known for its role in tissue fibrosis, its other actions
include it being a potent chemoattractant for mast cells
[16]. Thus, the finding in the present study that TGF-
is expressed in renal mast cells raises the potential for
a vicious cycle, whereby TGF- produced by mast cells
leads to TGF-–dependent mast cell chemotaxis, more
TGF–, and an exuberant fibrotic response in neigh-
boring tissues.
In contrast to most other bone marrow–derived cells,
mast cells are extruded as immature precursor cells that
differentiate and mature at the site of their migration
[38]. The cellular and soluble components that lead to
mast cell differentiation and maturation are not well
understood, although SCF acting through its cognate
receptor, c-kit, is thought to play a pivotal role in a range
of aspects of mast cell differentiation and function [14].
Consistent with findings in chronic glomerulonephritis
[9], the present study also documented increased SCF
in association with renal injury and localized its expres-
sion to areas of tubulointerstitial injury, as previously
reported in human biopsies [9]. In addition to its chemo-
tactic actions, SCF, through its interaction with c-kit, is
also a potent mediator of mast cell degranulation [39].
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Fig. 5. Photomicrograph showing stem cell
factor (SCF)–stained tubular epithelium (brown)
in an area of tubulointerstitial injury, adjacent
to a glomerulus (*) from a 5/6 nephrectomized
rat (magnification 280).
The finding in the present study of the late overexpres-
sion of SCF suggests that this factor may have a role in
the perpetuation of mast cell–mediated renal injury
rather than the initiation of the pathologic process.
In the present study, ACE inhibition not only attenu-
ated the structural and functional injury in subtotal ne-
phrectomized rats, but also reduced mast cell infiltration
and chemokine expression. In particular, IL-8/gro-, dra-
matically overexpressed following subtotal nephrectomy,
was normalized by ACE inhibition. Together, the find-
ings of the present study indicate that mast cell infiltra-
tion and related chemokine expression are prominent
and early features following renal mass that may contrib-
ute pathogenetically to progressive renal injury.
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